Previous 10 | Next 10 |
Verrica Pharmaceuticals ( NASDAQ: VRCA ) added ~7% pre-market Monday after RBC Capital Markets upgraded the dermatology drug developer, citing a potential FDA nod for its lead asset VP-102. The upgrade comes weeks after Verrica ( VRCA ) resubmitted its marketing application fo...
Verrica Pharmaceuticals ( NASDAQ: VRCA ) resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of VP-102 to treat a viral skin infection called molluscum contagiosum (MC). The FDA had declined to approve the company's NDA in March 202...
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone WEST CHESTER, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a d...
Registration Stability Batch for VP-102 Completed and Placed on Stability Process Validation Batches Successfully Manufactured Verrica Reaffirms its Expected Q1 2023 NDA Resubmission for VP-102 WEST CHESTER, Pa., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....
Verrica Pharmaceuticals press release ( NASDAQ: VRCA ): Q3 GAAP EPS of $0.00 beats by $0.14 . Revenue of $8.3M beats by $4.05M . For further details see: Verrica Pharmaceuticals GAAP EPS of $0.00 beats by $0.14, revenue of $8.3M beats by $4.05M
Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq...
WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO,...
Verrica Pharmaceuticals press release ( NASDAQ: VRCA ): Q2 Non-GAAP EPS of -$0.32 in-line. Revenue of $0.2M misses by $0.11M . For further details see: Verrica Pharmaceuticals Non-GAAP EPS of -$0.32 in-line, revenue of $0.2M misses by $0.11M
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun working with Piramal Pharma Solutions for production of bulk solution and reaffirms ...
The Company earns $8 Million Phase 3 Milestone Payment WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventi...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...